Experts sound off after Trump and NASA fast-track a nuclear reactor on the moon: ‘The whole proposal is cock-eyed'
'The whole proposal is cock-eyed and runs against the sound management of a space program that is now being starved of money,' national security analyst, nuclear expert and author Joseph Cirincione told The Independent.
Nuclear has been used in space since the 1960s. That's nothing new. The U.S. launched its first test reactor into orbit in 1965, and the former Soviet Union has sent up dozens more.
NASA says that a new 100-kilowatt reactor could be used to power a future base at the lunar South Pole, and fuel prospective missions to Mars and beyond. Nuclear would help to fill gaps in solar energy that occur when that side of the moon is in darkness for two weeks.
The majority of space experts have said that placing a reactor on the moon is possible, so, why is NASA's current plan 'cock-eyed?' The problem is the proposed timeline.
Interim NASA Administrator Sean Duffy, who also serves as President Donald Trump's Secretary of Transportation, pushed to expedite the project, detailed in a memo this week. Duffy said the administration wanted to have a nuclear reactor ready to launch by 2030. Earlier this year, China and Russia announced a plan to build a nuclear reactor for a lunar base by 2035.
'The first country to do so could potentially declare a 'keep-out' zone which would significantly inhibit the United States from establishing a planned Artemis presence if not there first,' Duffy said.
NASA first announced in 2021 that it would put a reactor on the moon 'within a decade.' In 2024, NASA then said that their target date for delivery a reactor to the Earth-based launchpad was the early 2030s. But, Cirincione says essentially no progress has been made.
'It was in the last Trump administration that NASA had put out a press release, they had a YouTube video, they had these announcements about how they're going to develop these small, modular nuclear reactors for use on the moon, and it was going to be ready by 2026,' said Cirincione, who is vice-chair of the Center for International Policy, a non-profit that advocates for a peaceful approach to foreign policy.
'Oh, really? So, where is it?'
Ultimately, the expert believes a nuclear reactor on the moon could take up to 20 years to become a reality.
NASA would need a working launch vehicle, a small and adaptable reactor, and the ability to land on the moon. Right now, the SpaceX Starship is the only vehicle option – but it has exploded during several of its test flights.
NASA has been working with Boeing on a Space Launch System - the main competitor to Space X's Starship - but that program would be canceled under the Trump administration's proposed cuts which slash 24 percent from NASA's overall budget.
Landing on the moon is no picnic, and attempts by Japanese space companies in 2023 and 2025 ended in crashes.
There are also the scientific and technological advances needed for the nuclear reactors. The reactors must be able to withstand harsh conditions on the moon, including temperatures swings from 250 degrees Fahrenheit during the day to minus 400 degrees at night.
'Small modular nuclear reactors, it turns out, are always just around the corner – a corner you never get to turn,' Cirincione said.
Many scientists and nuclear energy experts have shared in Cirincione's skepticism.
Dr. Kathryn Huff, a former nuclear energy official at the U.S. Department of Energy, and professor at the University of Illinois at Urbana-Champaign, wrote in a Bluesky social media post that she's not 'bullish' on 'unrealistic timelines.'
'The 2030 target does not align well with recent budgetary trends…' she explained in a statement, shared by the university. 'Accelerating the FSP program could come at the expense of other critical priorities, including earth science, climate observation and space-based weather forecasting – all core elements of NASA's public-serving mission.'
Dr. Alfredo Carpineti, an Italian astrophysicist, wrote in IFLScience this week that the proposal is 'unfeasible.'
'Even if we allow landing the nuclear reactor on December 31, 2030, the timing is really too short for something that must not have any faults if you want to operate it safely,' Carpineti wrote.
Others were more optimistic about NASA's accelerated timeline.
Sebastian Corbisiero, a senior program manager at Idaho National Laboratory who leads the Energy Department's space reactor program, told The Independent that a nuclear reactor on the moon is 'doable' by 2030.
'Nuclear reactor technology has been around for decades, so its well known,' he said. 'Some key differences with a space reactor is that it needs to fit on a rocket, so there are mass and volume requirements; and that the system needs to operate in vacuum – so components will need to be built to survive that environment.'
Dr. Bhavya Lal, a former associate administrator for technology, policy, and strategy at NASA, and former aerospace executive Roger Myers, recently argued that it would be possible to have nuclear reactor on the moon by 2030, and it would take $3 billion to do so.
'It's possible, but it will require serious commitment,' Lal told The Independent.
But even if plans are speeded up, Lal says there's no need to worry about the prospect of the moon blowing up. It's 'simply not grounded in science,' she said.
Solve the daily Crossword

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
How the unraveling of two Pentagon projects may result in a costly do-over
By Alexandra Alper WASHINGTON (Reuters) -Donald Trump's Navy and Air Force are poised to cancel two nearly complete software projects that took 12 years and well over $800 million combined to develop, work initially aimed at overhauling antiquated human resources systems. The reason for the unusual move: officials at those departments, who have so far put the existing projects on hold, want other firms, including Salesforce and billionaire Peter Thiel's Palantir, to have a chance to win similar projects, which could amount to a costly do-over, according to seven sources familiar with the matter. Trump took office vowing to rid the government of what he calls waste and abuse. The website of the Department of Government Efficiency, the agency he created to spearhead those efforts, lists over $14 billion in Defense Department contracts it claims to have cancelled. But seven months into his presidency, some of his own actions have complicated DOGE's work, from firing the Pentagon's inspector general to issuing an executive order prioritizing speed and risk-taking in defense acquisitions. Coupled with high-level vacancies in the Navy and Air Force that persisted well into the summer, the moves limit oversight of the Pentagon's contracting process and risk wasting hundreds of millions of additional taxpayer dollars as old projects are thrown out and new projects are agreed to, Reuters reporting based on sources, internal emails and documents, shows. 'There is a very real sense that we are in the regulatory Wild West with this administration – and it should come as no surprise that the traditional limits of 'normal contracting' are repeatedly going to be pushed and pressed in this environment,' said Franklin Turner, a federal contracting lawyer at McCarter & English. He said it is legal for the government to terminate any contract "for convenience," but said the Pentagon would be on the hook to reimburse the companies for wind-down costs plus take on the cost of any new replacement project. Trump officials say the administration is striving to make the contracting process more efficient. "Defense Secretary Hegseth is doing a great job restoring a focus on warfighters at the DOD while carrying out the American people's agenda to more effectively steward taxpayer dollars," White House Deputy Press Secretary Anna Kelly said in a statement. Pentagon Press Secretary Kingsley Wilson said the agency is taking "swift action" to fix the "antiquated" defense contracting process by implementing Trump's executive orders. "This is how we will rebuild the military with necessary speed while ensuring taxpayer dollars are spent wisely in the process,' she added. 'STRATEGIC PAUSE' In 2019, Accenture said it had won a contract to expand an HR platform to modernize the payroll, absence management, and other HR functions for the Air Force with Oracle software. The project, which includes other vendors and was later expanded to include Space Force, grew to cost $368 million and was scheduled for its first deployment this summer at the Air Force Academy. An April "status update" on the project conducted by the Air Force and obtained by Reuters described the project as "on track," with initial deployment scheduled for June, noting that it would end up saving the Air Force $39 million annually by allowing it to stop using an older system. But on May 30, Darlene Costello, then-Acting assistant Secretary of the Air Force, sent out a memo placing a "strategic pause" on the project for ninety days and calling for the study of alternate technical solutions, according to a copy of the memo seen by Reuters that was previously unreported. Costello, who has since retired, was reacting to pressure from other Air Force officials who wanted to steer a new HR project to SalesForce and Palantir , three sources said. Palantir co-founder Thiel was an early backer of President Donald Trump and has close ties with key Washington lawmakers, including Vice President JD Vance, whom he supported in a 2022 U.S. Senate race. Palantir in April won a $30 million contract from the U.S. Immigration and Customs Enforcement to develop an operating system that identifies undocumented immigrants and tracks self-deportations, its largest single award from the agency among 46 federal contract actions since 2011. The Air Force said in a statement that it "is committed to reforming acquisition practices, assessing the acquisition workforce, and identifying opportunities to improve major defense acquisition programs." Accenture, Costello, Palantir and SalesForce did not respond to requests for comment. Space Force, which operates within the Air Force, was set to receive the Air Force's new payroll system in the coming months. But it is also pulling out of the project because officials there want to launch yet another HR platform project to be led by Workday, according to three people familiar with the matter. The service put out a small business tender on May 7 for firms to research HR platform alternatives, with the goal of selecting a company that will recommend Workday as the best option, the people said. Space Force did not respond to multiple requests for comment. Now the Air Force and Space Force "want to start over with vendors that do not meet their requirements, leading to significant duplication and massive costs," said John Weiler, director of the Information Technology Acquisition Advisory Council, a government-chartered nonprofit group that makes recommendations to improve federal IT contracting. Oracle said in a statement it was "working closely with DOGE to accelerate the government's transformation to modern technology at the best price for the taxpayer." 'BEYOND EXASPERATED' In 2022, the Honolulu-based Nakupuna Companies took over a 2019 project with other firms to integrate the Navy's payroll and personnel systems into one platform using Oracle software and known as "NP2". The project, which has cost about $425 million since 2023, according to the Government Accountability Office, was set to be rolled out earlier this year after receiving a positive review by independent reviewer and consulting firm Guidehouse in January, according to a copy obtained by Reuters. But the head of Navy's human resources, now retired Admiral Rick Cheeseman, sought to cancel the project according to a June 5 memo seen by Reuters, directing another official to "take appropriate contractual actions" to cancel the project. Navy leaders instead mandated yet another assessment of project, according to a memo seen by Reuters, leaving it in limbo, two sources said. Cheeseman's reason for trying to kill the project was his anger over a decision by DOGE earlier this year to cancel a $171 million contract for data services provider Pantheon Data that essentially duplicated parts of the HR project. In an email obtained by Reuters, he threatened to withhold funding from the Nakupuna-led project unless the Pantheon contract was restored. "I am beyond exasperated with how this happened," Cheeseman wrote in a May 7 email to Chief Information Officer Jane Rathbun about the contract cancellation, arguing the Pantheon contract was not "duplicative of any effort." "From where I sit, I'm content taking every dime away from NP2 in order to continue this effort," he added in the email. Cheeseman did not respond to a request for comment. Rathbun and Pantheon Data declined to comment. The pausing of NP2 was "unexpected, especially given that multiple comprehensive reviews validated the technical solution as the fastest and most affordable approach," Nakupuna said in a statement, adding it was disappointed by the change because the project was ready to deploy. The Navy said it "continues to prioritize essential personnel resources in support of efforts to strengthen military readiness through fiscal responsibility and departmental efficiency." Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
Yahoo
9 minutes ago
- Yahoo
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (''2510') anticipated before the end of 2025 Updated '2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025 World Conference on Lung Cancer (WCLC) by ImmuneOnco DALLAS, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ('Instil') (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2025 financial results and provided a corporate update. Recent Highlights: In June, announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer In July, announced the Investigational New Drug (IND) application for '2510 was cleared by the U.S. FDA In July, ImmuneOnco, Instil's collaborator, announced preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of '2510 in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer (NSCLC) conducted in China by ImmuneOnco In August, ImmuneOnco announced that an abstract has been accepted for poster presentation at IASLC's 2025 World Conference on Lung Cancer (September 6th-9th, 2025), which will provide updated results from additional patients with relapsed/refractory squamous-NSCLC treated with '2510 as monotherapy Second Quarter 2025 Financial and Operating Results: As of June 30, 2025, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of $103.6 million, which consisted of $7.7 million in cash and cash equivalents, approximately $0.2 million in restricted cash, $84.1 million in marketable securities, and $11.7 million in long-term investments, compared to $115.1 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2024, consisting of $8.8 million in cash and cash equivalents, $1.8 million in restricted cash, and $104.5 million in marketable securities. Instil expects that its cash, cash equivalents, marketable securities and long-term investments as of June 30, 2025 will enable it to fund its operating plan beyond 2026. In-process research and development expenses were $10.0 million for both the three and six months ended June 30, 2025, compared to nil for both the three and six months ended June 30, 2024. Research and development expenses were $6.7 million and $12.1 million for the three and six months ended June 30, 2025, respectively, compared to $2.9 million and $10.2 million for the three and six months ended June 30, 2024, respectively. General and administrative expenses were $6.2 million and $15.3 million for the three and six months ended June 30, 2025, respectively, compared to $10.7 million and $23.1 million for the three and six months ended June 30, 2024, respectively. Restructuring and impairment charges were $0.5 million and $16.6 million for the three and six months ended June 30, 2025, respectively, compared to $0.5 million and $4.8 million for three and six months ended June 30, 2024, respectively. Net loss per share, basic and diluted were $3.24 and $7.55 for the three and six months ended June 30, 2025, respectively, compared to $2.29 and $6.03 for the three and six months ended June 30, 2024, respectively. Non-GAAP net loss per share, basic and diluted, were $2.88 and $4.21 for the three and six months ended June 30, 2025, respectively, compared to $1.57 and $3.95 for the three and six months ended June 30, 2024, respectively. Note Regarding Use of Non-GAAP Financial Measures In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles ('GAAP'). These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and restructuring and impairment charges. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil's financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil's operating results. In addition, these non-GAAP financial measures are among the indicators Instil's management uses for planning purposes and to measure Instil's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures. About Instil Bio Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. For more information visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'expects,' 'exploring,' 'future,' 'intends,' 'may,' 'plans,' 'potential,' 'projects,' 'targets' and 'will' or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements regarding our expectations with respect to the therapeutic potential of AXN-2510/IMM2510, clinical development of AXN-2510/IMM2510, including the initiation of clinical trials for AXN-2510/IMM2510 and the generation and presentation of clinical data for AXN-2510/IMM2510 and the timing thereof; research, development, regulatory and clinical plans for AXN-2510/IMM2510; Instil's expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties associated with the costly and time-consuming drug product development process and the uncertainty of clinical success; the risks inherent in relying on collaborators and other third parties, including for manufacturing and generating clinical data, and the ability to rely on any such data from clinical trials in China in regulatory filings submitted to regulatory authorities outside of China; the risks and uncertainties related to successfully making regulatory submissions and initiating, enrolling, completing and reporting data from clinical trials, particularly collaborator-led clinical trials, as well as the risks that results obtained in any clinical trials to date may not be indicative of results obtained in ongoing or future trials and that product candidates may otherwise not be effective treatments in their planned indications; risks related to macroeconomic conditions, including as a result of international conflicts and U.S.-China trade and political tensions, as well as interest rates, inflation, tariffs and other factors, which could materially and adversely affect our business and operations and those of our collaborators; the risks and uncertainties associated with the time-consuming and uncertain regulatory approval process and the sufficiency of Instil's cash resources; and other risks and uncertainties affecting Instil's plans and development programs, including those discussed in the section titled 'Risk Factors' in Instil's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 to be filed with the SEC, as well as Instil's other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law. Contacts: Investor Relations:1-972-499-3350 investorrelations@ INSTIL BIO, FINANCIAL DATA (Unaudited; in thousands, except share and per share amounts) Selected Condensed Consolidated Balance Sheet Data June 30, 2025 December 31, 2024 Cash, cash equivalents, restricted cash, marketablesecurities and long-term investments $ 103,632 $ 115,145 Total assets $ 230,986 $ 263,567 Total liabilities $ 99,316 $ 94,131 Total stockholders' equity $ 131,670 $ 169,436 Condensed Consolidated Statements of Operations Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Operating expenses: In-process research and development $ 10,000 $ — $ 10,000 $ — Research and development 6,743 2,921 12,114 10,177 General and administrative 6,157 10,706 15,266 23,130 Restructuring and impairment charges 540 508 16,622 4,783 Total operating expenses 23,440 14,135 54,002 38,090 Loss from operations (23,440 ) (14,135 ) (54,002 ) (38,090 ) Interest income 1,044 1,919 2,219 3,981 Interest expense (1,582 ) (1,999 ) (2,680 ) (3,980 ) Other rental income 2,242 — 4,484 — Other income (expense), net 342 (702 ) 385 (1,130 ) Net loss $ (21,394 ) $ (14,917 ) $ (49,594 ) $ (39,219 ) Net loss per share, basic and diluted $ (3.24 ) $ (2.29 ) $ (7.55 ) $ (6.03 ) Weighted-average shares used incomputing net loss per share, basic anddiluted 6,596,975 6,503,913 6,564,994 6,503,913 INSTIL BIO, of GAAP to Non-GAAP Net Loss and Net Loss per Share (Unaudited; in thousands, except share and per share amounts) Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Net loss $ (21,394 ) $ (14,917 ) $ (49,594 ) $ (39,219 ) Adjustments: Non-cash stock-based compensationexpense 1,824 4,173 5,319 8,688 Restructuring and impairmentcharges 540 508 16,622 4,783 Non-GAAP net loss $ (19,030 ) $ (10,236 ) $ (27,653 ) $ (25,748 ) Net loss per share, basic and diluted $ (3.24 ) $ (2.29 ) $ (7.55 ) $ (6.03 ) Adjustments: Non-cash stock-based compensationexpense per share 0.28 0.64 0.81 1.34 Restructuring and impairmentcharges per share 0.08 0.08 2.53 0.74 Non-GAAP net loss per share, basicand diluted* $ (2.88 ) $ (1.57 ) $ (4.21 ) $ (3.95 ) Weighted-average shares outstanding,basic and diluted 6,596,975 6,503,913 6,564,994 6,503,913 * Non-GAAP net loss per share, basic and diluted may not total due to in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Boston Globe
10 minutes ago
- Boston Globe
In troubled times on earth, the cosmos offers transcendent images
The Vera C. Rubin Observatory opened in June. Jointly operated by the National Science Foundation and US Department of Energy, it's located in northern Chile. The observatory's mission is to conduct a 10-year survey of the southern night sky. The images released so far have been astounding. They can be seen at The Vera C. Rubin Observatory. MARCOS ZEGERS/Marcos Zegers/The New York Times For almost as long as there has been photography, there have been photographs taken of the nighttime sky. The The Trifid and Lagoon nebulas, as seen from the Vera C. Rubin Observatory. VERA C. RUBIN OBSERVATORY/NSF/DOE/Vera C. Rubin Observatory Advertisement Rubin was an astronomer who did pioneering work on galactic rotation rates. The Hubble is named for the cosmologist Edwin Hubble, and Webb was a pioneering NASA administrator. Both the Hubble and Webb have the advantage of being in outer space, without Earth's atmosphere to contend with. The Rubin has the advantage of possessing the world's largest digital camera. Advertisement The size of a small SUV, the observatory's Legacy Survey of Space and Time camera weighs more than three tons and has a 3.2-gigapixel sensor. That means the camera's resolution is more than 1,500 times greater than that of a high-definition television. Not surprisingly, distant galaxies require, let alone deserve, a greater degree of detail than Netflix does. Calibrating the camera at the Vera C. Rubin Observatory. MARCOS ZEGERS/Marcos Zegers/The New York Times The observatory and telescopes afford a technological portal to a realm not just beyond comprehension but effectively beyond the imagination. 'The game I play is a very interesting one,' the Nobel Prize-winning physicist Richard Feynman once said. 'It's imagination in a tight straitjacket.' The celestial photography produced by the Rubin, Hubble, and Webb removes that straitjacket. Or as the poet Paul Celan once wrote, 'there are/still songs to sing beyond/mankind.' The LSST camera is a particularly stunning reminder that before it's anything else a camera is a machine. That machine can be a tool or a plaything, a means to create art or a selling point for a smartphone upgrade — or, yes, all of the above. Yet whatever the intended purpose, that machine executes the same action. A camera captures a moment in time that also existed in space. How artfully it does so is up to the camera operator. How memorably it does so is owing to some combination of the ability of that operator, the quality of the machine, and the nature of the subject. The "Cosmic Cliffs," photographed by the James Webb Space Telescope. NASA With art photography, the emphasis is on the ability of the operator: the artist. With celestial photography things are different. The operator rarely matters, albeit there are notable exceptions, one of which we'll also get to later. It's far more likely to be an algorithm than an actual person deciding where, when, and how to direct the lens. So rather than the emphasis being on the operator it's on these phenomenal machines and the even more phenomenal subjects they record: galaxies and nebulae and constellations. Advertisement Time assumes a different aspect with celestial photography. It becomes the intersection of the instant when the lens registers light — that's true of all photography — and the light years it took for that light to reach the lens. Space, too, assumes a different aspect. It becomes literally cosmic, a distance defying dimensionality, a realm so vast the human mind cannot begin to comprehend it even as the camera documents small slices of it — which is also to say small slices of that vastness. Galaxy M83, the Southern Pinwheel, in a photo mosaic taken by the Hubble Space Telescope. REUTERS/NASA A certain much-used cliché has it that a picture is worth a thousand words. Like most clichés, it has a basis in reality. It acknowledges the uniquely thick descriptive power of the photographic image. Here, though, words take a back seat to wonder. Images like these render meaningless adjectives like 'spectacular' and 'astonishing' and 'overwhelming.' They seem not just earthbound but Earth-bound. Actually, that's not quite right. When the words are names, rather than mere modifiers, then they have a capacity to evoke that complements the images' power to reveal: Virgo Cluster, Large Magellanic Cloud, Triffid Nebula, Pillars of Creation, Cosmic Cliffs, Christmas Tree Galaxy Cluster, Lagoon Nebula, Southern Pinwheel, Pandora's Cluster. The names are as poetic as the images are epic (far too weak a word, but you get the idea). Advertisement If the statement 'a picture is worth a thousand words' is one cliché that's relevant here, another is the question 'But is it art?' If we define art as beauty mediated through human handiwork, then of course these images are. They are so utterly alien to human experience as to confound our standard aesthetic ideas. They don't just transcend our sense of beauty. They transcend our sense of … everything. Vincent van Gogh, "The Starry Night," 1889. Museum of Modern Art Long before telescopes, let alone space telescopes, Joining their ranks is the photographer An-My Lê. Earlier this year, the Marian Goodman Gallery in New York showed her series Advertisement An-My Lê, "Sun Point View, Mesa Verde National Park, Colorado, 2024," from "Dark Star," 2024. Courtesy of the artist and Marian Goodman Gallery/© An-My Lê 'Dark Star' is both a marked departure for The series shares a dynamic with the images from Hubble, Webb, and Rubin: the stars above, a human viewer below. But 'Dark Star' crucially differs from them in two key respects. First, there's the matter of human agency. Lê is the image-maker here, not an algorithm or computer program. Comparing the photographs within the series, one is aware of the countless decisions she had to make in deciding where to place the camera, when to click the shutter, what to emphasize. Also, 'Dark Star' explicitly connects the cosmos with Earth. The Rubin and space-telescope images leave out the planet. What they show is out there — way, way out there. Part of the power of Lê's photographs is the way they include the Earth. Each has a horizon line in the lower portion of the image, serving as a further, internal frame. It's a frame felt as well as seen. A Dec. 24, 1968, photo that shows the Earth behind the surface of the moon during the Apollo 8 mission and Earth as seen from Apollo 17 in 1972. NASA As it happens, the two most famous astronomical images show Earth, not outer space. They were taken on Apollo missions: 'Earthrise,' from 1968, and 'The Blue Marble,' from 1972. Both look back at the planet, not out from. How much of the appeal of the Rubin and space-telescope images is that they let us leave terrestrial concerns so exceedingly far behind? In April, Lê gave a lecture at Harvard. It included slides from 'Dark Star.' 'Perhaps it's the right time to look for a little comfort in the cosmos,' she mused. Advertisement Globe staffer Matt Juul contributed to this article. Star songs for the starry-eyed Celestial photography lets us see the music of the spheres. Here are 10 tunes to listen to while star gazing. Mark Feeney can be reached at